The Vanderbilt-lngram Cancer Center (VICC) employs both internal and external review mechanisms to inform and support the strategic decisions made by the center and to provide feedback necessary for ongoing evaluation of the effectiveness of those decisions. Program Planning and Evaluation provides a structured approach for assessing our current status relative to strategic planning, identifying opportunities and formulating approaches for implementing the mission of the VICC. These processes ensure effective and well-coordinated use of Cancer Center Support Grant (CCSG) resources, institutional discretionary support and philanthropic funds. The significant progress of the VICC, described throughout this renewal application, continues to provide evidence in support of the effective use of both internal and external planning and evaluation processes. The Director has the ultimate responsibility and authority for setting priorities for the development of new research programs and shared resources; recruiting and retaining scientists and scientific leaders; selecting programs, projects and individuals to receive seed grant funding; determining use of VICC space and resources; and organizing the Center as a whole to promote scientific interactions and enhance productivity. To ensure the Director receives the best advice possible, she relies on several committees for identifying short- and long-term initiatives, implementing policies, evaluating processes and participating in decision-making activities. These working groups help manage Center affairs as well as provide the setting for the Senior Leaders to exchange ideas with Program Leaders, Shared Resource Managers, and External Advisors. Internal groups include the Executive Committee, Research Program Leaders Committee, Shared Resource Oversight Group, Minority Affairs and Health Disparities Taskforce, Translational and Therapeutic Taskforce Committee, Cancer Clinical Enterprise Committee and the Clinical Enterprise Executive Committee. Two external groups provide opportunities for comprehensive planning and evaluation processes within the VICC, the External Scientific Advisory Board and the Board of Overseers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-16
Application #
8379907
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
16
Fiscal Year
2012
Total Cost
$39,819
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Sierra, Johanna C; Asim, Mohammad; Verriere, Thomas G et al. (2018) Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut 67:1247-1260

Showing the most recent 10 out of 2462 publications